Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters …

Opexa intends to use the net proceeds from the offering to continue funding the ongoing Abili-T clinical study of Tcelna in patients with Secondary Progressive MS and for general corporate purposes (including working capital, research and development, business development and operational purposes).

Aegis Capital Corp. acted as sole book-running manager for the offering.

The offering was made pursuant to a shelf registration statement on Form S-3 that was filed by Opexa with the Securities and Exchange Commission (SEC) and declared effective by the SEC on December5, 2012. Copies of the prospectus supplement relating to and describing the terms of the offering are available on the SECs web site at http://www.sec.gov. Copies of the prospectus supplement relating to these securities may also be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18thFloor, New York, NY, 10019, via telephone at (212) 813-1010, or via email at prospectus@aegiscap.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Opexa

Opexas mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Companys leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patients peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.

About Multiple Sclerosis (MS)

Multiple Sclerosis is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.

While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. The Secondary Progressive form of MS represents about a third of the MS patient population.

About Tcelna

Follow this link:
Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters ...